Aptorum Group Limited

Biopharmaceutical company registered in the Cayman Islands with offices in Hong Kong and London, founded in 2010 and listed on the American market since 2018. Develops medicines for infectious disease, oncology and metabolic and neurological conditions, works on small molecules found with its own drug discovery platform and on projects licensed from academic partners, and runs subsidiaries for diagnostics and for therapeutic development.